Author Correction: Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation

Affiliations

• ¹ Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
• ² Bioinformatics Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029, Madrid, Spain.
• ³ Area of Cell and Developmental Biology, CNIC, 28029, Madrid, Spain.
• ⁴ Genomics Unit, CNIC, 28029, Madrid, Spain.
• ⁵ McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, 53705, USA.
• ⁶ Genomics Support Center Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, 9019, Tromsø, Norway.
• ⁷ Clinical Bioinformatics Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, 9019, Tromsø, Norway.
• ⁸ Department of Hematology, University Hospital of North Norway, 9019, Tromsø, Norway.
• ⁹ Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway. lorena.arranz@uit.no.
• ¹⁰ Associate Investigator, Norwegian Center for Molecular Medicine (NCMM), University of Oslo, 0349, Oslo, Norway. lorena.arranz@uit.no.